Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myosin-XV (MYO15A) is a very large unconventional myosin motor protein essential for the proper organization, elongation, and maintenance of actin-rich stereocilia in the inner ear hair cells, which are specialized organelles required for mechanotransduction—the process of converting sound vibrations into electrical signals for hearing. MYO15A has a unique, large N-terminal extension, an ATPase motor domain, IQ repeat domains, and a C-terminal tail containing specialized domains (MyTH4, FERM, SH3, PDZ ligand). It forms complexes with proteins such as whirlin and EPS8 to organize and stabilize the structure and function of stereocilia. Mutations in MYO15A cause DFNB3, a form of severe to profound autosomal recessive nonsyndromic deafness, by disrupting stereocilia assembly and/or maintenance. Mouse models and genetic studies in humans have extensively characterized both the gene and its functional consequences. MYO15A is not currently considered a direct drug target, but is a significant genetic biomarker for hereditary hearing loss[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myosin-XV (MYO15A).